BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:53 PM
 | 
Nov 05, 2007
 |  BC Extra  |  Top Story

Novacea falls after ending Asentar trial

NOVC lost $4.30 (60%) to $2.89 on Monday after it ended the Phase III ASCENT-2 trial of Asentar (DN-101) to treat androgen-independent prostrate cancer (AIPC) due to an "imbalance of deaths between the two treatment arms," as observed by the DSMB. NOVC said it and partner Schering-Plough...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >